Benzinga | Jun 3, 2021 12:32PM EDT

Hoth Therapeutics Unveils Preclinical Results of HT-KIT Therapeutic Program

* Hoth Therapeutics Inc (NASDAQ:HOTH) has reported results from a preclinical trial of HT-KIT, a new molecular entity under development to treat mast cell-derived cancers and anaphylaxis.

* HT-KIT is an mRNA frame-shifting therapeutic designed to specifically target the receptor tyrosine kinase KIT, which is required for the proliferation, survival, and differentiation of bone marrow-derived hematopoietic stem cells.

* Key findings of the mouse models found that HT-KIT: Reduces KIT expression and induces apoptosis of neoplastic human mast cells. Inhibits tumor growth in humanized xenograft mast cell neoplasia models. Reduces liver infiltration of neoplastic mast cells. Reduces tumor growth in isograft models of mast cell neoplasia. Reduces signs of mast cell leukemia in an isograft model of mutant mast cell neoplasia.

* Price Action: HOTH shares are up 2.29% at $1.57 during the market session on the last check Thursday.